Javier Cortés, MD, PhD

Javier Cortés is the Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials.

Articles by Javier Cortés, MD, PhD

Dr Cortés Discusses Final KEYNOTE-522 Results in Early-Stage TNBC

BySabrina Serani,Javier Cortés, MD, PhD

August 4th 2026

Javier Cortés, MD, PhD, discusses the final KEYNOTE-522 analysis, showing pembrolizumab plus chemotherapy sustains long-term survival benefit in early-stage TNBC.

How KEYNOTE-522 Permanently Changed Triple-Negative Breast Cancer Care

ByJavier Cortés, MD, PhD

Published: May 30th 2026 | Updated: August 24th 2026

Discover the final 7.8-year survival data from KEYNOTE-522 and see how adding pembrolizumab to chemotherapy drastically cuts recurrence for early TNBC.

Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355

ByJavier Cortés, MD, PhD

June 3rd 2020

Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.